United Kingdom · Question · Written question
UIN 28089
Givinostat
Original
Introduced
3 February 2025
Last action
10 February 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
10 February 2025
Summary
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) NHS England and (b) ITF Pharma UK on the provision of (i) resources and (ii) guidance to NHS trusts to enable them to take part in the Early Access Progr
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
3 February 2025
Written question
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) NHS England and (b) ITF Pharma UK on the provision of (i) resources and (ii) guidance to NHS trusts to enable them to take part in the Early Access Progr
Source: Commons
10 February 2025
Answer
ITF Pharma UK, the United Kingdom marketing authorisation holder for givinostat, is providing access to givinostat through a type of compassionate use scheme called an Early Access Programme (EAP). Under the EAP, givinostat is free to both patients taking...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-02-03/28089
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1761085
- uk · wq-1761085 · source updated 10 February 2025